Name
Boehringer Ingelheim International GmbH
What We Do
At Boehringer Ingelheim, we are working towards a future where earlier disease detection and intervention result in long-term, real-world outcomes that prevent vision loss for the millions of people affected worldwide.1 We are driving the science by exploring new therapeutic concepts and novel biomarkers and endpoints to enable early diagnosis and develop targeted treatments that work earlier in the disease before vision loss occurs. We have built an innovative and diverse pipeline in retinal conditions with limited or no available treatment options, including for diabetes-related eye diseases, neovascular age-related macular degeneration, and geographic atrophy. With our assets progressing through later stages of clinical development, we are now exploring overlapping disease mechanisms and expanding our research beyond the retina to address areas of greatest unmet need in eye health. 1WHO. Blindness and vision impairment. Available at: https://shorturl.at/mPeTQ. Accessed: March 2025.
Categories
Pharmaceuticals
Phone
+4961320
Address
Binger Str. 173
Ingelheim, 55216
Germany
Ingelheim, 55216
Germany